Dr. Reddy’s to acquire US prescription portfolio from Mayne Pharma for $105 million

Dr. Reddy’s to acquire US prescription portfolio from Mayne Pharma for $105 million.

The portfolio includes 40 approved off-market products, including approximately 45 commercial products, 4 products in development, and many generic products focused on women’s health.

[{"selector":"#anim-65fa6b5f-23bf-41af-a7a9-6afb322ab486 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

He also supports Dr. Reddy’s efforts to accelerate and develop affordable drugs for patients.

[{"selector":"#anim-65167e52-33b2-4611-86c6-d21d9f2c6295 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

For the fiscal year ending June 30, 2022, Mayne Pharma reported total acquisition portfolio revenue of $111 million.

[{"selector":"#anim-784158d5-b4c7-4395-a7a3-6267061eb034 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]